03:58 PM EST - Aeterna Zentaris Inc. : announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD). Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.15 at $2.00.
